Urine pH and Urinary Tract Infection

Urinary Tract Infections Clinical Trial

— PHURINE  

Official title:

Consequences of UTI on Urine pH

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04598971
• Other study ID #: 2020-00779
• Status: Recruiting
• Start date: August 1, 2020
• Est. completion date: December 13, 2021

Study information

• Verified date: October 2020
• Source: Centre Hospitalier Universitaire Vaudois
• Contact: Charlotte Desponds, BM
• Phone: +41795561934
• Email: Charlotte.Desponds[@]unil.ch
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Urinary tract infections (UTI) affect the urine pH and may lead to salt precipitation such as struvite. Bacteria with urease activity are known to alkalinise urine, but not much is known on how pH is changing over time during UTI.

This study aims at following urine pH progression at the time of diagnosis of UTI and during the treatment phase.

Description of the change in urine pH over time will help understanding the risk of struvite formation and potential timing of intervention.

Description:

Adults presenting with UTI symptoms will be screened for infection and instructed to monitor urine pH during the course of treatment and 1 week after. Urine pH will be measured by the patients using calibrated pH-stix. Type of bacteria, antibiotics, and the type of diet will be monitored during the study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: December 13, 2021
• Est. primary completion date: December 31, 2020
• Gender: All
• Age group: 18 Years and older

Eligibility

Group 1. Cystitis

Inclusion Criteria:

• Symptoms of dysuria, pollakiuria, no fever AND

• urine-stix positive for leucocytes OR positive culture (>10E5 cfu/ml)

Group 2. Pyelonephritis

Inclusion Criteria:

• Unilateral flank pain, pollakiuria, dysuria, fever (>38.5°C) AND

• urine-stix positive for leucocytes OR positive culture (>10E5 cfu/ml)

Exclusion Criteria (both groups):

• known urinary tract anatomic abnormalities

• Presence of a urine catheter

• Sepsis - septic shock

• Patient taking drug interfering with urine pH (diuretics, citrate, acetazolamide, topiramate,...)

• Patients with UTI diagnosed in the preceding month

• Patients having received antibiotics during the preceding month

• Male patient with a diagnosis of prostatitis

• Presence of infected kidney cyst

• Patient with diabetes

• Pregnant female

• Patient with obstructive pyelonephritis

Related Conditions & MeSH terms

• Infection
• Urinary Calculi
• Urinary Stone
• Urinary Tract Infections
• Urolithiasis

Locations

Country	Name	City	State
Switzerland	UniSanté	Lausanne	VD

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire Vaudois

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Urine pH	Urine pH is monitored by the patient every morning during the treatment phase and 7 days after the end of treatment	21 days